Open Access

PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells

  • Authors:
    • Yabing Wang
    • Zhiyong Zhao
    • Wei Jiao
    • Zhaocai Yin
    • Wanjun Zhao
    • Hongguang Bo
    • Zilin Bi
    • Bingbin Dong
    • Bin Chen
    • Zheng Wang
  • View Affiliations

  • Published online on: November 1, 2022     https://doi.org/10.3892/etm.2022.11674
  • Article Number: 738
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prenylated rab acceptor 1 domain family member 2 (PRAF2) acts as an oncogene and is closely related to the occurrence and development of various tumors. The present study aimed to clarify the functional relevance of PRAF2 in the biological behaviors of breast cancer by determining the expression of PRAF2 in breast cancer tissues and the corresponding adjacent tissues. The gene phenotypes of PRAF2 in patients with breast cancer in The Cancer Genome Atlas database were predicted using a cancer data online analysis website: The University of Alabama at Birmingham Cancer Data Analaysis Portal (UALCAN). The mRNA and protein expression of PRAF2 was further examined in 37 pairs of fresh frozen breast cancer tissues and adjacent non‑tumor tissues by reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. High expression of PRAF2 was verified by RT‑qPCR in the breast cancer cell line, MCF‑7, and small interfering RNA (siRNA) technology was used to silence PRAF2. In the in vitro cell functional experiment, three groups were used: Negative control (NC) group, siRNA‑NC group and siRNA‑PRAF2 group. Cell Counting Kit‑8 (CCK‑8) and colony formation assays were conducted to analyze the effect of downregulation of PRAF2 on the proliferation of breast cancer cells. Transwell invasion and cell scratch assays were performed to examine the effect of downregulation of PRAF2 on the invasion and migration of breast cancer cells. UALCAN analysis results indicated that PRAF2 expression was upregulated in breast cancer compared with normal tissue samples (P<0.001). High expression of PRAF2 in breast cancer was associated with TNM stage and regional lymph node metastasis. RT‑qPCR results showed increased mRNA expression of PRAF2 in clinical tissue samples from 37 patients with breast cancer, compared with normal adjacent tissues (P<0.001). Protein expression of PRAF2 was also shown to be higher in the breast cancer MCF‑7 cells than in the MDA‑MB‑231 cells. Western blotting analysis combined with ImageJ software quantification showed that the relative expression of PRAF2 protein was significantly higher in clinical tissue samples from 37 patients with breast cancer (1.9750±0.0103) than that in normal adjacent tissues (0.9818±0.0140) (P<0.001). Western blotting analysis results indicated that transfection with siRNA PRAF2 in MCF‑7 cells decreased PRAF2 expression (P<0.001). The results of CCK‑8 and colony formation assays revealed that downregulation of PRAF2 expression suppressed the proliferation of MCF‑7 cells (P<0.05 and P<0.001, respectively). In addition, Transwell invasion and cell scratch assay results showed that downregulation of PRAF2 expression in MCF‑7 cells repressed invasion and migration of cancer cells (P<0.001). Overall, PRAF2 expression was significantly higher in breast cancer tissues than normal adjacent tissues, and was closely related to TNM stage and regional lymph node metastasis in breast cancer. PRAF2 was found to act as an oncogene that is able to promote breast cancer cell proliferation and invasion. Thus, PRAF2 may be a potential prognostic factor in patients with breast cancer and a potential target for the treatment of breast cancer metastasis.

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Zhao Z, Jiao W, Yin Z, Zhao W, Bo H, Bi Z, Dong B, Chen B, Wang Z, Wang Z, et al: PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells. Exp Ther Med 24: 738, 2022
APA
Wang, Y., Zhao, Z., Jiao, W., Yin, Z., Zhao, W., Bo, H. ... Wang, Z. (2022). PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells. Experimental and Therapeutic Medicine, 24, 738. https://doi.org/10.3892/etm.2022.11674
MLA
Wang, Y., Zhao, Z., Jiao, W., Yin, Z., Zhao, W., Bo, H., Bi, Z., Dong, B., Chen, B., Wang, Z."PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells". Experimental and Therapeutic Medicine 24.6 (2022): 738.
Chicago
Wang, Y., Zhao, Z., Jiao, W., Yin, Z., Zhao, W., Bo, H., Bi, Z., Dong, B., Chen, B., Wang, Z."PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells". Experimental and Therapeutic Medicine 24, no. 6 (2022): 738. https://doi.org/10.3892/etm.2022.11674